MACM
ENZY

March Altus Capital Management’s Enzymotec Ltd ENZY Stock Holding History

March Altus Capital Management’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-681,778
Closed -$5.13M – 24
2014
Q4 		$5.13M Hold
681,778
– – 2.34% 18
2014
Q3 		$4.55M Buy
681,778
+614,315
+911% +$6.63M 1.81% 21
2014
Q2 		$915K Sell
67,463
-260,499
-79% -$4.37M 0.34% 29
2014
Q1 		$7.22M Buy
327,962
+125,000
+62% +$3.31M 2.32% 22
2013
Q4 		$5.48M Buy
+202,962
New +$4.83M 1.66% 27

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AP
Alydar Partners Boston, Massachusetts $185M AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

March Altus Capital Management's ENZY Position: Q1 2015 in Review

March Altus Capital Management sold out of Enzymotec Ltd (ENZY) in Q1 2015, closing a stake of 681,778 shares — an estimated $5.13M sold.

March Altus Capital Management first reported a position in ENZY in Q4 2013 and held it in 5 quarters. The position peaked at $7.22M in Q1 2014. 20 funds tracked by Wall St. Rank hold ENZY as of Q1 2015.

  • March Altus Capital Management reported no remaining Enzymotec Ltd position as of Q1 2015 after selling out during the quarter.
  • March Altus Capital Management sold 681,778 Enzymotec Ltd shares in Q1 2015, an estimated $5.13M.
  • March Altus Capital Management first reported a position in Enzymotec Ltd in Q4 2013 and held it in 5 quarters.
  • March Altus Capital Management's Enzymotec Ltd position peaked at $7.22M in Q1 2014.
  • 20 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q1 2015.

Based on March Altus Capital Management's 13F filing for Q1 2015, filed 15 May 2015.